Clozapine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Clozapine: From Treatment-Resistant Schizophrenia to Manic Bipolar Affective Disorder
One-Sentence Summary
Clozapine is an atypical antipsychotic long established for treatment-resistant schizophrenia. The TxGNN model predicts it may also be effective for Manic Bipolar Affective Disorder, with 6 clinical trials and 20 publications currently informing this direction, including one completed Phase 2 RCT testing clozapine directly in treatment-resistant mania.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Treatment-resistant schizophrenia |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L2 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, clozapine is an atypical (multi-receptor) antipsychotic with antagonist activity across dopamine (D1–D4), serotonin (5-HT2A/2C), muscarinic, histaminergic and adrenergic receptors, and it is the established gold-standard treatment for treatment-resistant schizophrenia.
Bipolar affective disorder and schizophrenia sit on an overlapping neuropsychiatric spectrum, sharing dopaminergic and serotonergic dysregulation, and both conditions are frequently managed with the same class of antipsychotic agents. Clozapine is already used off-label internationally for treatment-resistant mania and treatment-resistant bipolar disorder when patients fail conventional mood stabilisers and antipsychotics, which is consistent with the TxGNN prediction rather than a wholly novel therapeutic hypothesis.
This mechanistic plausibility is reinforced by a dedicated NIMH-funded double-blind Phase 2 trial (NCT00029458) evaluating clozapine specifically in treatment-resistant manic bipolar disorder, and by a body of secondary literature (systematic reviews and clinical reviews) describing clozapine’s use in this population, giving the prediction a reasonable evidentiary anchor beyond model output alone.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00029458 | Phase 2 | Completed | 42 | Double-blind study evaluating the safety and efficacy of clozapine specifically for the manic phase of treatment-resistant bipolar disorder |
| NCT05603104 | Phase 3 | Recruiting | 1254 | Intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression after first-line treatment failure; not exclusively a clozapine trial |
| NCT07047651 | Phase 4 | Recruiting | 40 | Pharmacotherapy combined with recovery-oriented programmes for treatment-resistant schizophrenia and treatment-resistant bipolar disorder |
| NCT06993662 | Phase 1 | Active, not recruiting | 107 | Combination of pharmacotherapy and cognitive behavioural psychotherapy for mental health disorders under a recovery framework |
| NCT03651674 | N/A | Unknown | 200 | Longitudinal MRI study of brain structure/function change after electroconvulsive therapy in schizophrenia and bipolar disorder |
| NCT07398365 | N/A | Recruiting | 100 | Observational medical phenotyping of NHS General Adult Psychiatry inpatients |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32182485 | 2020 | Systematic review/meta-analysis | Journal of Psychiatric Research | Assessed clinical efficacy and adverse effect profile of clozapine in bipolar disorder |
| 25346322 | 2015 | Systematic review | Bipolar Disorders | Evaluated efficacy and safety of clozapine for treatment-resistant bipolar disorder |
| 33719158 | 2021 | Review | Bipolar Disorders | Summarised current evidence and future directions for clozapine in bipolar disorder |
| 31488793 | 2019 | Review | Psychiatria Danubina | Clozapine’s anti-suicidal, anti-aggressive and anti-impulsive properties proposed as a potential treatment for suicidality in bipolar disorder |
| 33460070 | 2020 | Review | Acta Psychiatrica Scandinavica | Evidence-based review of treatment options for bipolar mania, including antipsychotic and mood stabiliser choices |
| 37068038 | 2023 | Pharmacoepidemiological cohort | Journal of Clinical Psychopharmacology | Asian consortium study of clozapine prescribing patterns for bipolar disorder |
| 40174308 | 2025 | Real-world nationwide cohort | Journal of Psychiatric Research | Evaluated anti-suicidal effectiveness of clozapine, lithium and valproate in schizophrenia and bipolar disorder using a national database |
| 31567198 | 2021 | Review | American Journal of Therapeutics | Discussed rapid clozapine titration protocols in schizophrenia and bipolar disorder |
| 16432528 | 2006 | Review | Molecular Psychiatry | Reviewed treatment-resistant bipolar disorder, noting antipsychotic augmentation strategies |
| 11280956 | 2001 | Review | Bulletin of the Menninger Clinic | Early review of pharmacotherapy options, including clozapine, for treatment-resistant bipolar disorder |
UK Market Information
Clozapine is currently recorded in this dataset as Not Marketed, with 0 marketing authorisations on file. No licence records (PL numbers, product names, dosage forms) are available to report.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: this evidence pack flags a blocking data gap — MHRA/manufacturer product-label warnings and contraindications have not yet been retrieved — which must be resolved before any formal safety review can proceed (see Conclusion below).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 double-blind RCT (NCT00029458) directly tested clozapine in treatment-resistant manic bipolar disorder, and this is corroborated by a systematic review/meta-analysis and several narrative reviews — sufficient to meet an L2 evidence threshold. However, the only Phase 3 trial identified is not clozapine-specific, and a blocking data gap on product-label safety information (warnings/contraindications) currently prevents a full safety assessment.
To proceed, the following is needed:
- MHRA-approved product label (SmPC) warnings and contraindications for clozapine (currently a blocking data gap)
- Confirmation of detailed mechanism of action data
- A clozapine-specific Phase 3 RCT in bipolar mania/treatment-resistant bipolar disorder
- Clarification of UK marketing authorisation status, given the current “Not Marketed” record in this dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.